Please provide your email address to receive an email when new articles are posted on . LipiFlow has consistently demonstrated safety and efficacy in treating meibomian gland dysfunction. The review ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Patients reported reduced symptoms of dry eye for 12 ...

TEL AVIV, Israel--(BUSINESS WIRE)--Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today ...

Meibomian gland dysfunction (MGD) is underdiagnosed and undertreated, with asymptomatic disease far more common than symptomatic disease. As the condition progresses, patients who were initially ...

Dry eye disease is a condition that afflicts millions of people worldwide, causing constant discomfort and affecting their quality of life. One of the key culprits behind this condition is meibomian ...

Meibomian gland dysfunction, an etiological factor of dry eye disease, showed promising results in response to treatment with intense pulsed light. A review published in Clinical Ophthalmology found ...

A short course of azithromycin matched a standard doxycycline regimen for relief of severe meibomian gland dysfunction (MGD) and caused fewer adverse events (AEs), a randomized trial showed. The ...

TEL AVIV, Israel & MELBOURNE, Australia--(BUSINESS WIRE)--Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a new therapeutic class of Ophthalmic Keratolytics for ocular ...

You’ve probably never heard of Meibomian Gland Dysfunction. But chances are, you may experience it at some point in your life. It’s something 69 News reporter Jaccii Farris knows firsthand. Over the ...

—AZR-MD-001 is a Potential First-in-Class Therapy Targeting Meibomian Gland Dysfunction (MGD), the Root Cause of Dry Eye Disease (DED) and Contact Lens Discomfort (CLD)— Azura Ophthalmics Ltd., a ...